{"filing":{"accession_number":"0001193805-26-000770","cik":"0001768224","ticker":"ARCT","company_name":"Arcturus Therapeutics Holdings Inc.","form":"8-K","filing_date":"2026-06-05","report_date":null,"primary_document":"e665552_8k-arct.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1768224/000119380526000770/e665552_8k-arct.htm"},"events":[{"id":6538,"run_id":5724,"accession_number":"0001193805-26-000770","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This Item 5.07 filing discloses the final results of Arcturus Therapeutics' 2026 annual stockholder meeting held on June 5, 2026, including voting outcomes on three proposals: election of eight directors, advisory approval of named executive officer compensation (\"say-on-pay\"), and ratification of Deloitte as independent auditor. All three proposals passed with substantial majorities, and the detailed vote tallies are provided for each director nominee and proposal.","company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","filing_date":"2026-06-05","form":"8-K","submitted_at":null,"items":[{"id":4958,"accession_number":"0001193805-26-000770","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 filing discloses the final results of Arcturus Therapeutics' 2026 annual stockholder meeting held on June 5, 2026, including voting outcomes on three proposals: election of eight directors, advisory approval of named executive officer compensation (\"say-on-pay\"), and ratification of Deloitte as independent auditor. All three proposals passed with substantial majorities, and the detailed vote tallies are provided for each director nominee and proposal.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T21:21:10.052318+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4958,"accession_number":"0001193805-26-000770","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 filing discloses the final results of Arcturus Therapeutics' 2026 annual stockholder meeting held on June 5, 2026, including voting outcomes on three proposals: election of eight directors, advisory approval of named executive officer compensation (\"say-on-pay\"), and ratification of Deloitte as independent auditor. All three proposals passed with substantial majorities, and the detailed vote tallies are provided for each director nominee and proposal.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T21:21:10.052318+00:00","company_name":"Arcturus Therapeutics Holdings Inc.","ticker":"ARCT","filing_date":"2026-06-05"}]}